Data From Intercept’s Pivotal Phase 3 POISE Trial of Its FXR Agonist Obeticholic Acid to Treat Primary Biliary Cirrhosis and Other Key Obeticholic Acid Data to be Presented at EASL 2014

[GlobeNewswire] – NEW YORK — Intercept Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver diseases, today announced … more

View todays social media effects on ICPT

View the latest stocks trending across Twitter. Click to view dashboard

See who Intercept is hiring next, click here to view